- Home
- CAPR vs JMIA Comparison
CAPR vs JMIA Comparison
Compare CAPR & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- JMIA
- Stock Information
- Founded
- CAPR 2005
- JMIA 2012
- Country
- CAPR United States
- JMIA Germany
- Employees
- CAPR N/A
- JMIA N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- JMIA Catalog/Specialty Distribution
- Sector
- CAPR Health Care
- JMIA Consumer Discretionary
- Exchange
- CAPR Nasdaq
- JMIA Nasdaq
- Market Cap
- CAPR 453.9M
- JMIA 412.7M
- IPO Year
- CAPR N/A
- JMIA 2019
- Fundamental
- Price
- CAPR $11.66
- JMIA $4.41
- Analyst Decision
- CAPR Strong Buy
- JMIA Buy
- Analyst Count
- CAPR 8
- JMIA 2
- Target Price
- CAPR $33.75
- JMIA $7.88
- AVG Volume (30 Days)
- CAPR 3.0M
- JMIA 4.0M
- Earning Date
- CAPR 08-06-2025
- JMIA 08-05-2025
- Dividend Yield
- CAPR N/A
- JMIA N/A
- EPS Growth
- CAPR N/A
- JMIA N/A
- EPS
- CAPR N/A
- JMIA N/A
- Revenue
- CAPR $17,363,588.00
- JMIA $154,854,000.00
- Revenue This Year
- CAPR $258.96
- JMIA $10.62
- Revenue Next Year
- CAPR $8.02
- JMIA $7.08
- P/E Ratio
- CAPR N/A
- JMIA N/A
- Revenue Growth
- CAPR N/A
- JMIA N/A
- 52 Week Low
- CAPR $3.52
- JMIA $1.60
- 52 Week High
- CAPR $23.40
- JMIA $15.04
- Technical
- Relative Strength Index (RSI)
- CAPR 50.35
- JMIA 66.55
- Support Level
- CAPR $9.65
- JMIA $4.09
- Resistance Level
- CAPR $10.56
- JMIA $4.71
- Average True Range (ATR)
- CAPR 1.21
- JMIA 0.34
- MACD
- CAPR -0.02
- JMIA 0.08
- Stochastic Oscillator
- CAPR 70.08
- JMIA 81.37
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.